ReconTop Stories

Exactech and JointMedica Announce First Hip Resurfacing Procedure with Polymotion® Hip Implant

January 10, 2023

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, is pleased to announce the first hip resurfacing surgery was successfully completed using the novel JointMedica Polymotion® hip implant that is based on a metal-on-polyethylene articulation.

This surgery was performed by hip resurfacing specialist Jim MacKenzie, MD, in Calgary, Canada, who is also celebrating a milestone accomplishment of 20 years of completing hip resurfacing procedures. The Polymotion hip implant addressed the unique pathology of the patient’s hip that could not be addressed with legacy, metal-on-metal hip resurfacing implants.

“Many patients benefit from hip resurfacing. Having performed this procedure for more than 20 years, it is exciting to see new developments in the hip resurfacing space. I look forward to being able to provide this technology for my patients,” said Dr. MacKenzie.

Exactech announced the acquisition of a minority interest in JointMedica Limited earlier in 2022. Both companies are collaborating to deliver the next generation of hip resurfacing to the global market through the Polymotion implant, which has yet to receive clearance from the U.S. Food and Drug Administration. The implant system will become available in targeted markets on a country-by-country basis following regulatory clearances.

According to Exactech’s Chief Strategy Officer Sharat Kusuma, MD, “Historically, the concept of hip resurfacing has intellectually appealed to surgeons all over the world. In fact, Sir John Charnley, the credited inventor of the modern total hip replacement, intuitively performed hip resurfacing in his initial cohort of hip arthritis patients [rather than total hip arthroplasty]. Sir Charnley’s early hip resurfacings failed due to inferior materials, not due to flaws in the procedure itself.”

Dr. Kusuma continued, “Exactech is thrilled to now partner with the credited inventors of modern hip resurfacing, Derek McMinn MD, FRCS, and Ronan Treacy, MD, FRCS, and JointMedica, to deliver the next generation of metal-on-advanced-polyethylene hip resurfacing to the market.”

About JointMedica

JointMedica is an orthopaedic design and development “Think Tank,” intending to advance and disseminate new concepts which result in the creation of innovative orthopaedic implants. Our objective is to form close relationships with key orthopaedic surgeons, empowering the creation of products that are highly innovative while at the same time meeting the heightened expectations of patients along with the stringent quality and safety standards that apply to modern orthopaedic implants.



About Exactech

Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit for more information and connect with us on LinkedInVuMediYouTubeTwitter and Instagram.

Polymotion® & POLYMOTION®. Registered trademarks of JointMedica

Alteon®. Registered trademark of Exactech


Morgan Lee
Marketing Communications Senior Manager

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button